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Abstract
Background—Eosinophils in blood and sputum in chronic obstructive pulmonary disease 
(COPD) have been associated with more frequent exacerbations, lower lung function, and 
corticosteroid responsiveness. We hypothesized increased eosinophils are associated with a severe 
COPD phenotype, including exacerbation frequency, and tested whether blood eosinophils reliably 
predict sputum eosinophils.
Methods—Comprehensive baseline data on SPIROMICS subjects, recruited for a range of 
COPD severity for smokers with ≥20 pack year history, included demographics, questionnaires, 
clinical assessments, quantitative computed tomography (QCT), blood and induced sputum.
Findings—Significantly, stratification by mean sputum eosinophils ≥1·25% (N=827) was 
associated with reduced FEV1 % predicted (differences: 10% pre-bronchodilator, 4·7% post-
bronchodilator), QCT density measures for emphysema and air trapping, and exacerbations treated 
with corticosteroids (p=0·002). In contrast, stratification by mean blood eosinophils ≥200/µL 
(N=2499) showed that FEV1 % predicted was significant between low and high blood subgroups, 
but less than observed between sputum subgroups (blood eosinophil group differences: 4·2% pre-
bronchodilator, 2·7% post-bronchodilator), slightly increased airway wall thickness (0·02 mm, 
p=0·032), greater symptoms (p=0·037), and wheezing (p=0·018), but no evidence of association 
with COPD exacerbations or other indices of severity. Blood eosinophils showed weak although 
significant association with sputum eosinophils (ROC AUC=0·64, p<0·001), but with a high false 
discovery rate (72%). Elevated sputum eosinophils, with or without blood eosinophils, were 
associated with lower lung function. Elevated blood eosinophils only in combination with elevated 
sputum eosinophils were associated with COPD exacerbations.
Interpretation—Stratification of SPIROMICS subjects by blood eosinophils alone showed 
minimal clinical differences and no association with exacerbations, whereas stratification by 
sputum eosinophils was associated with larger phenotypic differences and COPD exacerbations. 
Importantly, increased blood eosinophils did not reliably predict airway eosinophils in induced 
sputum.
Keywords
COPD severity; airway eosinophilia; emphysema; hyperinflation; air-trapping
INTRODUCTION
Airways inflammation in chronic obstructive pulmonary disease (COPD) is thought to be 
characterized by increased neutrophils,1 macrophages,2 proteases, IL-6, IL-8, and Th1 
cytokines3 while airways inflammation in asthma is traditionally characterized by increased 
eosinophils, and Th2 cytokines.4 However, reports challenge these presumptive differences 
between asthma and COPD. The ECLIPSE study reported that in COPD, sputum neutrophils 
are weakly associated with lung function and health status, and not associated with 
exacerbations, emphysema or systemic inflammation.1 ECLIPSE also reported a mean 1·3% 
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sputum eosinophil level in 359 subjects with COPD,1 but did not observe blood eosinophil 
associations with radiologic measure of emphysema or with COPD exacerbations and 
hospitalizations. ECLIPSE reported ≥2% (150/µL) blood eosinophils associated with 
evidence of higher FEV1, lower St. Georges Respiratory Questionnaire (SGRQ) and 
modified Medical Research Council scores.5 Other COPD studies have reported increased 
eosinophils associated with exacerbations and greater hyperinflation on QCT,6,7 suggesting 
Th2 inflammation may contribute to disease progression. Moreover, increased epithelial Th2 
signature gene expression has been associated in two COPD cohorts with more severe 
airflow obstruction.8 Eosinophils may represent a potential biomarker in COPD since 
eosinophilia is related to corticosteroid responsiveness.1,9–11 In a phase II clinical trial, anti-
IL-5 receptor therapy reduced the COPD exacerbation rate in a subgroup of patients with 
elevated blood and sputum eosinophilia.12
Determination of disease severity in COPD is complex and involves more than lung function 
assessments; additional clinical characteristics have been incorporated in successive 
revisions of the GOLD severity stages.13 Current classification includes lung function, 
symptom scores and exacerbation frequency. Thus, severity of COPD is dependent on 
multiple characteristics; eosinophilic inflammation may contribute.
Reports suggest blood eosinophil counts may represent a useful surrogate measure of airway 
eosinophils in COPD,11,14 although blood eosinophils appear to correlate poorly with 
sputum eosinophils in asthma,15,16 and do not distinguish between asthma-dominant, 
COPD-dominant or asthma/COPD overlap populations.17 However, larger studies of 
comprehensively phenotyped COPD patients often lack robust sputum eosinophil data.18–21 
Thus it is uncertain whether peripheral eosinophils accurately predict airway eosinophils.
We investigated the hypotheses that blood and sputum eosinophils in subjects with a history 
of tobacco use were associated with a more severe COPD phenotype identified by 
diminished lung function, QCT measurements of emphysema or air-trapping, clinical COPD 
characteristics, and exacerbations. We also investigated relationships of blood and sputum 
eosinophils to determine whether blood eosinophils reliably predicted sputum eosinophils. 
These hypotheses were evaluated in the comprehensively characterized SPIROMICS cohort.
22
 A portion of these studies were presented as an abstract at the 2016 American Thoracic 
Society meeting.23
METHODS
Subjects
Subjects with current or former history of tobacco use (≥20 pack-year), recruited to include 
specific groups of smokers with preserved lung function (31%), GOLD stages 1 and 2 
(41%), and GOLD stages 3 and 4 (21%) and a control group of nonsmokers, age 40–80 
(N=2737), were enrolled in the Subpopulations and Intermediate Outcome Measures in 
COPD Study (SPIROMICS) at six clinical sites and additional subsites.22 COPD was 
defined in long-term smokers as a post-bronchodilator FEV1/FVC ratio <0·7. Subjects 
underwent extensive baseline phenotypic characterization including lung function 
assessment pre- and post-bronchodilator with albuterol and ipratropium, CT total lung 
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capacity and residual volume (TLC and RV) using QCT indicators for emphysema (% 
voxels less than −950 Hounsfield Units [HU]) at TLC, and air-trapping (% voxels less than 
−856 HU) at RV, airway metrics (VIDA Diagnostics, Iowa)24 and parametric response 
mapping (PRM) for functional small airways disease (fSAD),25 collection of blood (for 
DNA, RNA, plasma, sera, IgE and complete blood cell counts [CBC]), urine, 6 minute walk 
distance, GOLD stage, BODE index, COPD Assessment Score (CAT), St. Georges 
Respiratory Questionnaire (SGRQ), and administered questionnaires for medical history, 
exacerbations (retrospective from past year), hospitalizations, respiratory exposures, and 
medications.22 In a subset (see online supplement Figure S1 detailing subset of SPIROMICS 
with induced sputum cell counts), induced sputum was performed. Subjects with a primary 
asthma diagnosis were excluded, but all subjects were asked if they had ever had a health 
care professional say that they had asthma (“prior asthma label”). In the N=2499 enrolled 
ever smokers, the mean ± standard deviation for blood eosinophil count was 200 ± 240/µL 
(median=190/µL; full range 0–8300/µL); a higher eosinophil cutpoint of 300/µL was also 
examined. See supplement for additional information on the selection of stratification 
cutpoints, reproducibility, and other details.
Sputum Induction and Processing
SPIROMICS subjects with post-bronchodilator FEV1 % predicted ≥35% were eligible for 
sputum induction with saline solutions, nebulized for three 7 min intervals each. 
Expectorated sputum samples were processed as described in detail in the supplement. 
Cytospin slides were read by the central reading center. Slides were available for 1001 
subjects. Differential counts (500–600 total cells) which had ≤100 leukocytes total (N=179) 
or ≥80% squamous (N=11) were excluded as unacceptable. The mean sputum eosinophil % 
(± standard deviation) for the subgroup with acceptable sputum (N=827) was 1·25 ± 4·25% 
(median=0·3%; full range 0–75%); a higher cutpoint of 2% for sputum eosinophils was also 
examined. (See supplement on subject distribution with induced sputum.)
Statistical Analyses
Subjects were stratified by eosinophil mean blood counts or mean sputum %. Demographic 
and biomarker data are presented as means ± standard deviations, or medians (25%–75% 
interquartile range) for continuous variables, and as % positive for categorical variables. 
Measures not meeting Kolmogorov-Smirnov test for normal distribution, were transformed 
by log, or square root values. Continuous variables were tested by parametric or non-
parametric tests (see supplement; SAS 9·2, or Sigmastat 12·5). Categorical variables were 
analyzed using Chi-square or Fisher Exact tests. Correlations were examined by Pearson 
Correlation test or linear regression. Receiver Operating Curve (ROC) analysis was 
performed for blood eosinophil prediction of sputum eosinophils. The False Discovery Rate 
(= False Positives / False Positives + True Positives) was examined.26 Classification tree 
analysis examining sputum and blood eosinophils to model exacerbations was performed 
using R part routines in R software package. Variables with a p value <0·05 were accepted as 
significant.27
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RESULTS
Subject Demographics
Demographic characteristics of SPIROMICS subjects stratified by mean blood eosinophils 
(< or ≥200/µL) and by mean sputum eosinophils (< or ≥1·25%) are shown in Table 1. For 
those subjects with low compared to high blood eosinophils, age, gender, race, BMI, 
cigarette smoking pack-years, % current smoker, and % use of inhaled corticosteroids (ICS) 
statistically differed, although differences between the groups were small (<10%). The 
proportion of current smokers was less in the ≥200/µL eosinophil group, but the number of 
cigarettes smoked each day was the same. Medications (supplement Table S1) did not differ, 
except for ICS treatment, higher in the ≥200/µL eosinophil group (Table 1). Total serum IgE 
levels (range 5·5–1660) and sputum eosinophils % differed in blood eosinophil groups, but 
those with a “prior asthma label” or childhood asthma did not differ (Table 1). Median 
sputum eosinophil % in low and high blood eosinophil groups differed (p<0.001), but were 
lower than the overall sputum eosinophil mean of 1·25%.
In subjects stratified by mean sputum eosinophils at 1·25%, age, gender, race, BMI, smoking 
pack-years, cigarettes/day, and % current smokers did not differ (Table 1. Differential counts 
for leukocytes in sputum eosinophil groups are presented in supplement Table S2). 
Medication use in the sputum cohort did not differ, except increased use of ICS, and inhaled 
or nebulized bronchodilators in the ≥1·25% sputum eosinophils group (supplement Table 
S1). Higher sputum eosinophils, unlike higher blood eosinophils, did not have significantly 
increased IgE levels compared to low sputum eosinophil group. Nevertheless, IgE levels in 
low and high sputum eosinophil groups were similar to IgE levels in low and high blood 
eosinophil groups, respectively. In addition, the sputum eosinophil ≥1·25% group had 
elevated blood eosinophils (230/µL, p<0·001) and a greater proportion of subjects reporting 
a “prior asthma label” (p=0·003). Similar results for blood or sputum eosinophil 
stratification were obtained with higher cutpoints (≥300/mL blood eosinophils levels, or 
≥2% sputum eosinophils, respectively; supplement Table S3).
Spirometry
Dividing by blood eosinophils, the ≥200/µL high eosinophil group had marginally lower 
values for pre-bronchodilator FEV1 % predicted (4·2%), and no difference post-
bronchodilator (0·6%), compared to the <200/µL low eosinophil group (Table 2). The 
sputum eosinophils ≥1·25% group had greater differences between pre bronchodilator and 
post-bronchodilator FEV1 % predicted (10 and 5·7%, respectively), compared to <1.25% 
group. Due to safety exclusion of subjects with post-bronchodilator FEV1 % predicted <35% 
from sputum induction, fewer GOLD Stages 3 and 4 subjects were included in the sputum 
cohort. However, baseline and post-bronchodilator FEV1 % predicted showed larger 
differences between low and high sputum eosinophil groups than observed between low and 
high blood eosinophil groups. Reversibility of baseline FEV1 % predicted, was larger in the 
elevated sputum eosinophil group (p<0·001), but did not differ for the blood eosinophil 
groups. Similar observations were found between subgroups stratified by ≥300/µL blood and 
≥2% sputum eosinophil cutpoints (supplement Table S4).
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Imaging
Indices of emphysema and air trapping at TLC and RV24, respectively, did not differ 
between blood eosinophil groups (Table 3). In contrast, significantly higher emphysema 
indices (% voxels <−950 HU) in left upper and lower lobes, and right upper lobe were 
observed in sputum eosinophil ≥1·25%. In addition, air trapping (% voxels <−856 HU) and 
functional small airways disease assessed by parametric response mapping (PRM fSAD,25) 
were higher in subjects with ≥1·25% sputum eosinophils.
There was a small, 0·02 mm increase in average airway wall thickness at RB1 (prespecified 
pathway in apical segment of right upper lobe) for elevated blood eosinophils, but not for 
elevated sputum eosinophils. Neither blood nor sputum stratification showed any difference 
in airway tapering (an index of bronchiectasis).
The higher ≥300/µL blood eosinophil cutpoint did not alter density measures for emphysema 
or air trapping, but reduced significance for RB1 airway wall thickness. The higher ≥2% 
sputum eosinophil cutpoint maintained significance for both emphysema and air trapping 
indices (supplement Table S5).
Clinical Characteristics
Among subjects with ≥1·25% sputum eosinophils, there were fewer GOLD Stage 0 and 
increased GOLD Stage 2 subjects compared to subjects with <1·25% sputum eosinophils 
(p=0·0006, Table 4). The 6 min walk distance, BODE Index and COPD Assessment Score 
did not differ for either blood or sputum eosinophil stratifications. The blood eosinophil 
≥200/µL group showed significantly higher frequency of self-reported wheezing (Table 4). 
St. George Respiratory Questionnaire (SGRQ) symptom score was also higher in the 
≥200/µL blood eosinophil subgroup; both SGRQ total and symptom scores were 
significantly higher in the ≥1·25% sputum eosinophils subgroup.
The higher ≥300/µL blood eosinophils cutpoint showed a significant difference for GOLD 
Stages (supplement Table S6). The higher ≥2% sputum eosinophil cutpoint maintained 
significance for GOLD Stages, SGRQ total and symptoms scores, and became significant 
for BODE Index, SGRQ Impact and self-reported wheezing.
Exacerbations
Blood eosinophils ≥200/µL and sputum eosinophils ≥1·25% were tested for association with 
exacerbations (Table 5). Elevated blood eosinophils were not associated with any of the 
different categories of reported exacerbations. In contrast, elevated sputum eosinophils were 
associated with increased proportions of subjects with exacerbations requiring 
corticosteroids, exacerbations requiring treatment with any drug, and severe exacerbations 
requiring emergency department visit. The higher ≥300/µL blood eosinophil cutpoint did not 
show any association with exacerbations, but the higher ≥2% sputum eosinophil cutpoint 
demonstrated significance for all categories of reported COPD exacerbations (supplement 
Table S7). Tree classification of sputum and blood eosinophil association with exacerbations 
selected sputum eosinophils before blood eosinophils and showed similar cutpoints, 
sequentially < or ≥1·9% for sputum eosinophils and < or ≥ 176/µL for blood eosinophils, 
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supporting the 2% and 200/µL cutpoints investigated for sputum and blood eosinophils in 
this study (supplement Figure S2). Sputum eosinophils >1·9% identified a subgroup of 
subjects with exacerbations (27 of 119 or 23%). In contrast, those with <1.9% sputum 
eosinophils showed a lower proportion of subjects with exacerbation (65 of 692 or 9%).
Blood Eosinophil Prediction of Sputum Eosinophils
ROC analyses demonstrated a relatively weak, although significant relationship for blood 
eosinophils to predict sputum eosinophils ≥1·25% (Figure 1, AUC=0·63, p<0·0001); ROC to 
predict ≥2% sputum eosinophils was similar (supplement Figure S3). Highest sensitivity and 
specificity for predicting sputum eosinophils ≥1·25% and ≥2% were found at 150/µL and 
250/µL blood eosinophils, respectively, with equivalent, significant AUCs observed at 
adjacent cutpoints (supplement Table S8). Nevertheless, both associations had very large 
false discovery rates; 72% for blood eosinophils ≥150/µL to predict sputum eosinophils 
≥1·25% (false negative rate of 22%), and 74% for blood eosinophils ≥250/µL to predict 
sputum eosinophils ≥2% (false negative rate of 50%).
Combined Blood and Sputum Eosinophil Phenotypes
The correlation between sputum eosinophils and blood eosinophils was poor, but significant 
(Figure 2; correlation coefficient r=0·178, p<0·001). However, numerous subjects (42%) had 
discordant blood and sputum eosinophil levels; either high in blood or in sputum, but not in 
the other compartment. Lung function and reported exacerbations for subjects in the two 
discordant quadrants and two concordant quadrants were compared (Table 6). High sputum 
eosinophil groups, without or with high blood eosinophils, had the lowest lung function. 
Lung function for the high blood eosinophil group without high sputum eosinophils did not 
differ from the group with low eosinophils in both blood and sputum. However, high blood 
eosinophil groups only in combination with elevated sputum eosinophils had more COPD 
exacerbations; exacerbations treated with corticosteroids (p=0·006) or severe (p=0·013) were 
significant.
Additional Stratifications for Blood and Sputum Eosinophil Subgroups
Subjects were stratified by “prior asthma label” or ICS use and examined for interaction 
with high eosinophils (blood eosinophils ≥200/mL or sputum eosinophils ≥1·25%) on lung 
function and exacerbations. No interactions were significant (supplement Tables S9, and 
S10). Subjects who did not have acceptable sputum slides for various reasons (N=1498) 
were stratified by blood eosinophil counts to determine whether these subjects represented a 
phenotype with different characteristics (supplement Table S11). There was slightly higher 
proportion of subjects using ICS, lower lung function and increased proportions of GOLD 
Stage 3 and 4 subjects as would be expected in these groups which contained subjects with 
lower lung function and therefore ineligible for sputum induction, but otherwise resembled 
the larger cohort of smokers.
Another stratification examined whether blood eosinophil groups < or ≥200/µL showed 
differences when restricted to just those subjects in the sputum cohort (supplement Table 
S12). The sputum cohort divided into blood eosinophil subgroups had slightly greater 
proportion of current smokers, less ICS use and slightly better lung function, but did not 
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show the same radiologic, clinical or exacerbation diffierences observed for sputum 
eosinophil stratification.
We examined whether associations with worse lung function and quality of life, and greater 
exacerbations, emphysema, and air trapping in the high sputum eosinophil group were due 
to elevated sputum neutrophils in addition to high sputum eosinophils. There was no 
difference in mean sputum neutrophil % between high and low sputum eosinophil groups 
(Table S2). Stratification of the sputum cohort into 4 groups based on < or ≥1·25% 
eosinophils + < or > 68% neutrophils (mean ± std deviation for sputum neutrophils: 68% 
± 21%), confirmed differences across low and high sputum eosinophil groups but did not 
show significant post-hoc differences between the high eosinophil + high neutrophil and 
high eosinophil + low neutrophil subgroups (Supplement additional results, Table S13).
DISCUSSION
The results of this study from the SPIROMICS cohort, a smoking cohort that includes a 
spectrum of COPD severity defined by GOLD stages, confirms that elevated sputum 
eosinophils, but not blood eosinophils alone, identify a subset of COPD subjects with more 
severe airflow obstruction, worse quality of life, greater emphysema and air trapping, and 
exacerbations. Using sputum eosinophil stratification at either the mean, ≥1·25%, or ≥2%, 
we found significant associations with COPD exacerbations, including severe and those 
requiring corticosteroid therapy. In addition, significant associations were found for lower 
lung function, baseline and post-bronchodilation including increased bronchodilator 
reversibility; respiratory symptoms; emphysema and air trapping by QCT; and COPD 
severity by GOLD Stage. In contrast, blood eosinophils alone, at ≥200/µL, or the even 
higher cutpoint at ≥300/µL, showed no association with COPD exacerbations, and 
associations with other phenotypic markers were smaller or non-significant. Although there 
was an increase in SGRQ symptom scores for higher eosinophils in both blood and sputum 
compartments, and wheeze (found only for blood, possibly due to the larger N for that 
group) the differences between low and high eosinophil groups for these variables were 
greater in the sputum group. In addition, there was no difference in CAT scores for either 
blood or sputum, which tends to diminish the validity for this observation. Importantly, 
although the relationship between blood and sputum eosinophilia was statistically 
significant, blood eosinophils did not reliably predict sputum eosinophils, showing a 72–
74% false-discovery rate and a 50% false negative rate for sputum eosinophils ≥2%. Lung 
function data stratified by high and low sputum and blood eosinophils showed no 
relationship with high blood eosinophils unless combined with high sputum eosinophils, 
while high sputum eosinophils even in the absence of blood eosinophils was associated with 
lower lung function. However, COPD subjects with both high sputum and blood eosinophils 
exhibited both decreased lung function and more frequent exacerbations. These findings 
among current and former smokers in a large multicenter cohort with a specified range of 
COPD severity have important implications for proposed use of blood eosinophils alone as a 
predictive biomarker to guide individualized COPD therapies.
Our results extend observations from previous studies in COPD cohorts, including 
ECLIPSE, which focused primarily on neutrophilic airways inflammation,1 and, though 
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reporting eosinophil presence,5 did not address association of eosinophilia with indices of 
COPD severity.4,5 The importance of our findings and of Th2 inflammation in COPD are 
emphasized by the recent report of Th2 gene expression overlap in airway epithelial samples 
from asthma and COPD cohorts,8 and by shared clinical and biologic characteristics 
between asthma and COPD reported in several recent studies.5,7,17,28–29 However, 
differences are noted between SPIROMICS and other COPD cohorts. COPD gene enrolled a 
larger cohort (N=10,000) which was slightly older (minimum 45 yr) and had a lower 
smoking history (>10 pack year), but phenotyping with induced sputum was not performed.
30
 Sputum was also unavailable in Copenhagen General Population Study,20 WISDOM,21 
INSPIRE, and TRISTAN.31 Although these studies report exacerbations correlating with 
blood eosinophils, it is important to note that the entry requirements included past history of 
COPD exacerbations which can impact the results since a past history of exacerbation is the 
most important factor predicting future exacerbations.18
In addition emphasis on persistent Th2 inflammation in COPD32, has focused on eosinophils 
as predictors of exacerbations. Bafadhel and colleagues reported a cluster analysis using 
blood and sputum biomarkers; peripheral blood eosinophils predicted sputum eosinophil-
associated exacerbations of COPD.6 Sputum airway and peripheral blood eosinophils have 
been used to direct corticosteroid treatment and reduce occurrence of COPD exacerbations.
9–11
 The ECLIPSE study reported that 1483 subjects if stratified by blood eosinophils did 
not differ for COPD exacerbation rate in the previous year.5 We confirm that higher blood 
eosinophils are not associated with COPD exacerbations except combined with elevated 
sputum eosinophils or with other characteristics such as a previous history of exacerbation.18 
However, in SPIROMICS higher sputum eosinophils alone are associated with exacerbations 
even in mild to moderate COPD.
Eosinophil levels have been suggested to indicate response to corticosteroids, anti-IL5, or 
anti-IL5 receptor therapy.9–12,33 In a retrospective analysis of two COPD exacerbation 
studies with long-acting beta-agonists and inhaled corticosteroids, Pascoe showed that 
subjects with higher blood eosinophils had greater reduction in COPD exacerbations.34 
These observations suggest eosinophils may be important in development or potential 
biomarker of some COPD exacerbations. However, two factors may influence previous 
observations correlating elevated blood eosinophil groups with greater COPD exacerbations; 
selection criteria requiring recent exacerbation and perhaps lower lung function are both 
related to future COPD exacerbations and may be surrogate markers of increased sputum 
eosinophils. Elevated blood eosinophils, if also combined with elevated sputum eosinophils, 
associate with COPD exacerbations, as shown for the SPIROMICS cohort in this report. 
However, blood eosinophils alone were not associated with exacerbations, even when 
combined with “prior asthma label”. This latter observation contrasts with the association of 
blood eosinophils ≥275/µL with all cause mortality in 662 subjects, but that study found no 
change after exclusion of subjects with asthma.35 Blood eosinophils in our study were 
associated with COPD exacerbations only in the context of higher sputum eosinophils.
We also examined other characteristics in the blood and sputum eosinophil subgroups of 
SPIROMICS subjects that might suggest overlap with asthma: bronchodilator reversibility, 
IgE levels, and childhood asthma. Blood eosinophils at two different cutpoints (either ≥200 
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or ≥300/µL) did not have higher levels of acute bronchodilator reversibility, while elevated 
sputum eosinophils showed greater reversibility. IgE levels were significantly higher in the 
elevated blood eosinophil group, although not in sputum, but IgE levels in SPIROMICS 
blood and sputum eosinophil subgroups were well below median (91 IU/ml) and high IgE 
cutpoint (173 IU/ml) reported in a recent study of asthma-COPD overlap syndrome.36 Only 
≥2% sputum eosinophils showed increased report of childhood asthma, which represent a 
small subgroup (12·5%).
There was greater use of prescribed inhaled corticosteroids in both high blood and sputum 
eosinophil groups. This was observed despite an expected reduction in eosinophils with 
corticosteroid therapy. Use of corticosteroids in the higher eosinophil groups potentially 
reflects individuals more likely to have had exacerbations, consistent with GOLD guideline 
recommendations for corticosteroids in COPD patients with frequent exacerbations.13 
Limitations of this report include somewhat milder COPD in the group who were able to 
successfully perform induced sputum. For safety reasons, SPIROMICS subjects with post-
bronchodilator FEV1 % predicted <35% did not have sputum induction, limiting the sputum 
subgroup to GOLD Stages 0–3. Although our cohorts (both for blood and sputum eosinophil 
analyses) included smoking subjects (>40 pack years) with preserved lung function, these 
subjects were included because they have been shown to have greater symptoms, 
exacerbations, activity limitations and radiologic evidence of airway disease.37 These 
findings are consistent with early COPD in this subgroup.37 Although SPIROMICS 
exacerbations data was retrospective, validity of retrospective data for future risk of COPD 
exacerbation has been shown in the ECLIPSE where self-reported exacerbation from the 
previous year had predicted exacerbations during the first year of follow up, more accurately 
than all other variables examined.18 An additional limitation, at least in clinical settings, is 
the difficulty in performing accurate sputum analysis. Even in the SPIROMICS network 
with centralized training for sputum induction and processing there were still reasons 
preventing sputum analysis on all eligible subjects as indicated in the supplemental methods. 
However analysis of those who did not have sputum analysis, stratified by blood eosinophils 
did not differ substantially from the larger cohort.
Of interest, longitudinal follow-up of the SPIROMICS cohort may be used to confirm the 
observations of Hospers and colleagues that peripheral eosinophils are associated with all 
cause mortality over a period of 30 years.35 Alternatively, the differences in decline of lung 
function associated with blood eosinophils < or ≥2% observed in the much smaller study 
over 9 years by Rogliani and colleagues should be examined in the larger SPIROMICS 
cohort longitudinally.38 In summary, using the larger and comprehensive phenotypic 
characterization of the SPIROMICS cohort, we show that stratification by elevated sputum 
eosinophil inflammation identified a subgroup with more severe COPD, having decreased 
lung function, greater emphysema and air trapping, and greater COPD exacerbations. 
Peripheral blood eosinophils identified a subgroup with decreased lung function without 
other indices of more severe COPD, specifically exacerbations unless examined on the 
background of elevated sputum eosinophils. Moreover, blood eosinophils did not accurately 
predict sputum eosinophils. These observations confirm the importance of assessing 
eosinophils in the airways. In the future, it will be important to follow these subjects with 
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higher sputum eosinophilia longitudinally to determine whether long term effects on the 
progression of COPD.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Research in Context
Evidence before this study
A PubMed search for original research reports containing information on eosinophils, 
sputum, blood and COPD through May 2017 yielded 154 articles, of which 32 were 
reviews. Addition of either “severity” or “exacerbation” reduced publication numbers to 
33 (7 reviews) or 35 (1 review), respectively. However, many of these reports have further 
limitations, either lacking sputum or blood eosinophil data for comparison, not 
specifically focused on severity of COPD including exacerbations, or containing small 
numbers of subjects (<100/group) which limit the power to make conclusions for broader 
COPD populations. Generally eosinophils in COPD have been linked to more frequent 
exacerbations and responsiveness to corticosteroid therapy, suggesting more severe 
disease. Often studies are primarily in populations who have met selection criteria for 
clinical trials that include the presence of COPD exacerbations. Thus, comparison of 
blood eosinophils and sputum eosinophils for association with a more severe COPD 
phenotype has not been well studied in a general smoking population with a broad range 
of COPD severity, nor has possible substitution of blood eosinophils as a biomarker for 
sputum eosinophils in COPD populations been carefully examined.
Added value of this study
This study demonstrates that in a large, comprehensively characterized smoking cohort 
with a broad range of COPD severity, elevated sputum eosinophils, but not blood 
eosinophils alone, had significant associations with multiple measures of COPD severity, 
including exacerbations, increased emphysema and air trapping, St. George Respiratory 
Questionnaire scores and GOLD spirometric stage. Blood eosinophils demonstrated weak 
association with sputum eosinophils and as a single biomarker had few significant 
associations with COPD severity and exacerbations. However, this study does 
demonstrate that elevated blood eosinophils in combination with elevated sputum 
eosinophils show associations with COPD exacerbations and severity.
Implications of all the available evidence
Increased sputum eosinophils from subjects with a broad range of COPD severity 
identify those more likely to have severe disease and exacerbations. Blood eosinophils as 
a single biomarker do not accurately predict sputum eosinophils, and do not show any 
association with disease severity or exacerbations unless observed in the background of 
increased sputum eosinophils. The findings from this study will be important in the 
design of therapeutic trials which target eosinophilic inflammation in COPD. This article 
has an online data supplement.
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Figure 1. 
ROC analysis for blood eosinophil prediction of sputum eosinophil. Blood eosinophils at 
cutpoints from 50/µL (highest sensitivity) to 500/µL (lowest sensitivity) were examined for 
correct prediction of sputum eosinophils < or ≥1·25%. Although significant (p<0·001), the 
area under the curve (AUC) was only 0·63, demonstrating a lack of strength for the 
prediction. Maximum sensitivity and specificity were observed at a blood eosinophil 
cutpoint of 150/µL.
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Figure 2. 
Distribution of subject’s blood eosinophils with respect to sputum eosinophils. Although 
there is a significant association between blood and sputum eosinophils (EOS) (Pearson 
correlation coefficient r=0·178, p<0·001), use of the cutpoint ≥200/µL blood eosinophils 
(vertical red line) to predict sputum eosinophils ≥1·25% (horizontal red line) will mistakenly 
identify many subjects with lower sputum eosinophil% (lower right quadrant, pink shade) 
and miss many subjects with actual sputum eosinophils ≥1·25% (upper left quadrant, blue 
shade).
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